Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Targeting with talquetamab as a bridge to BCMA CAR-T shows no grade ≥3 CRS, 2% grade 3 ICANS and grade 1-2 talq unique toxicities, 71% ORR, post CAR-T 88% responded/54% CR, 2 grade ≥3 CRS, 1 grade 3 ICANS, 5% grade ≥3 infxns.”
Title: Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
Authors: Binod Dhakal, Othman Salim Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew James Rees, Patrick Costello, Mariola Alejandra Vazquez Martinez, Oren Pasvolsky, Charlotte B. Wagner, James A Davis, Omar A. Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo D Parrondo, Ciara L Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson, Jr., Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud R. Gaballa, Shonali Midha, Melissa Alsina, Douglas W Sborov, Krina K. Patel, Yi Lin, Christopher J Ferreri, Nico Gagelmann, Anupama Deepa Kumar, Doris K Hansen, Andrew J Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana
You can read the Full Article on Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
